ISTH/X
Jul 9, 2025, 13:59
Late-Breaking Insights from ISTH 2025: Rurioctocog Alfa Pegol in PUPs with Hemophilia A
The International Society on Thrombosis and Hemostasis (ISTH) recently shared a inviting post on X:
“Late-breaking from ISTH 2025! Dr. Robert Sidonio joins the ISTH Pulse Podcast to unpack game-changing Phase 3 trial results on rurioctocog alfa pegol in in previously untreated patients with severe hemophilia A. Listen now:”
Do not miss The Important in the world of Hematology, read Hemostasis Today.
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC